PMC:7402624 / 3614-4014 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T28","span":{"begin":96,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}

{"project":"LitCovid-PubTator","denotations":[{"id":"89","span":{"begin":21,"end":30},"obj":"Species"},{"id":"90","span":{"begin":191,"end":199},"obj":"Species"},{"id":"93","span":{"begin":31,"end":40},"obj":"Disease"},{"id":"94","span":{"begin":218,"end":226},"obj":"Disease"},{"id":"95","span":{"begin":351,"end":359},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Tax:2697049"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"Tax:9606"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D007239"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"MESH:C000657245"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":21,"end":25},"obj":"Disease"},{"id":"T28","span":{"begin":31,"end":40},"obj":"Disease"},{"id":"T29","span":{"begin":218,"end":226},"obj":"Disease"},{"id":"T30","span":{"begin":351,"end":359},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T45","span":{"begin":96,"end":102},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T46","span":{"begin":287,"end":288},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T19","span":{"begin":360,"end":372},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}

{"project":"LitCovid-sentences","denotations":[{"id":"T28","span":{"begin":75,"end":173},"obj":"Sentence"},{"id":"T29","span":{"begin":174,"end":373},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"tibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29). Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis.\nTaken together, this previ"}